drugset / Trial / NCT04715217
Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma
Phase 1/2
Unknown
24 enrolled
Shanxi Province Cancer Hospital
Novatim Immune Therapeutics (Zhejiang) Co., Ltd. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
Evaluation the safety,tolerability, preliminary efficacy,and PK/PD of CD19-CD22 CAR-T cells for the treatment of B cell lymphoma.
Timeline
- Start
- 2021-01-04
- Primary completion
- 2024-10-31
- Completion
- 2025-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19-CD22 CAR-T cells | Cell therapy | 0.5 cells/kg | Intravenous |
| Subject | CD19-CD22 CAR-T cells | Cell therapy | 2 cells/kg | Intravenous |
| Subject | CD19-CD22 CAR-T cells | Cell therapy | 5 cells/kg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | — |
| Background | Fluorine dara marina | Unknown | 30 mg/m2 | — |